Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMD-003 for EBV Positive Lymphomas
NCT02763254Phase 2Terminated
- Sponsor
- Kuur Therapeutics
- Start
- Nov 2016
- Primary completion
- Feb 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of baltaleucel-T in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), Post-transplant lymphoproliferative disease (PTLD), sponsored by Kuur Therapeutics. Started Nov 2016; status: terminated.
02
Drugs
baltaleucel-T
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)Post-transplant lymphoproliferative disease (PTLD)
Beyond the preview
Go deeper on NCT02763254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763254.